These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25708597)

  • 1. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.
    Roualdes O; Nougier C; Fretigny M; Talagrand E; Durand B; Negrier C; Vinciguerra C
    Haemophilia; 2015 May; 21(3):e202-e209. PubMed ID: 25708597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.
    Jourdy Y; Nougier C; Roualdes O; Fretigny M; Durand B; Negrier C; Vinciguerra C
    Haemophilia; 2016 Jul; 22(4):583-9. PubMed ID: 26915717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
    J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.
    Radic CP; Rossetti LC; Abelleyro MM; Tetzlaff T; Candela M; Neme D; Sciuccati G; Bonduel M; Medina-Acosta E; Larripa IB; de Tezanos Pinto M; De Brasi CD
    J Thromb Haemost; 2015 Apr; 13(4):530-9. PubMed ID: 25611311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
    Pezeshkpoor B; Gazorpak M; Berkemeier AC; Singer H; Pavlova A; Biswas A; Oldenburg J
    Ann Hematol; 2019 Aug; 98(8):1855-1865. PubMed ID: 30997536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein.
    Pahl S; Pavlova A; Driesen J; Oldenburg J
    Thromb Haemost; 2014 Jan; 111(1):58-66. PubMed ID: 24108539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Female hemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII.
    Cai XH; Wang XF; Dai J; Fang Y; Ding QL; Xie F; Wang HL
    J Thromb Haemost; 2006 Sep; 4(9):1969-74. PubMed ID: 16805874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.
    Loomans JI; van Velzen AS; Eckhardt CL; Peters M; Mäkipernaa A; Holmstrom M; Brons PP; Dors N; Haya S; Voorberg J; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Feb; 15(2):246-254. PubMed ID: 27943580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of four novel molecular changes in the promoter region of the factor VIII gene.
    Nougier C; Roualdes O; Fretigny M; d'Oiron R; Costa C; Negrier C; Vinciguerra C
    Haemophilia; 2014 Mar; 20(2):e149-56. PubMed ID: 24372689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
    Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay.
    Khanum F; Collins PW; Harris RL; Bowen DJ
    Haemophilia; 2014 Mar; 20(2):287-93. PubMed ID: 24118398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation.
    Zimmermann MA; Oldenburg J; Müller CR; Rost S
    Haemophilia; 2014 May; 20(3):e215-21. PubMed ID: 24602271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays.
    Valikhani A; Mirakhorly M; Namvar A; Rastegarlari G; Toogeh G; Shirayeh FV; Ahmadinejad M
    Transfus Apher Sci; 2021 Oct; 60(5):103194. PubMed ID: 34275734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.
    Guillet B; Lambert T; d'Oiron R; Proulle V; Plantier JL; Rafowicz A; Peynet J; Costa JM; Bendelac L; Laurian Y; Lavergne JM
    Hum Mutat; 2006 Jul; 27(7):676-85. PubMed ID: 16786531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
    Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
    Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM
    Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype.
    Oldenburg J; Pavlova A
    Hamostaseologie; 2010 Nov; 30(4):207-11. PubMed ID: 21057709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes.
    Bastida JM; González-Porras JR; Jiménez C; Benito R; Ordoñez GR; Álvarez-Román MT; Fontecha ME; Janusz K; Castillo D; Fisac RM; García-Frade LJ; Aguilar C; Martínez MP; Bermejo N; Herrero S; Balanzategui A; Martin-Antorán JM; Ramos R; Cebeiro MJ; Pardal E; Aguilera C; Pérez-Gutierrez B; Prieto M; Riesco S; Mendoza MC; Benito A; Hortal Benito-Sendin A; Jiménez-Yuste V; Hernández-Rivas JM; García-Sanz R; González-Díaz M; Sarasquete ME
    Thromb Haemost; 2017 Jan; 117(1):66-74. PubMed ID: 27734074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.